These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 29105742)

  • 61. Multiple myeloma in serologic complete remission after autologous stem cell transplantation: impact of bone marrow plasma cell assessment by conventional morphology on disease progression.
    Fernández de Larrea C; Tovar N; Rozman M; Rosiñol L; Aróstegui JI; Cibeira MT; Rovira M; Yagüe J; Bladé J
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1084-7. PubMed ID: 21215814
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
    Danziger SA; McConnell M; Gockley J; Young MH; Rosenthal A; Schmitz F; Reiss DJ; Farmer P; Alapat DV; Singh A; Ashby C; Bauer M; Ren Y; Smith K; Couto SS; van Rhee F; Davies F; Zangari M; Petty N; Orlowski RZ; Dhodapkar MV; Copeland WB; Fox B; Hoering A; Fitch A; Newhall K; Barlogie B; Trotter MWB; Hershberg RM; Walker BA; Dervan AP; Ratushny AV; Morgan GJ
    PLoS Med; 2020 Nov; 17(11):e1003323. PubMed ID: 33147277
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Practical diagnostic approaches to composite plasma cell neoplasm and low grade B-cell lymphoma/clonal infiltrates in the bone marrow.
    Hussein S; Gill K; Baer LN; Hoehn D; Mansukhani M; Jobanputra V; Bhagat G; Alobeid B
    Hematol Oncol; 2015 Mar; 33(1):31-41. PubMed ID: 24395190
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma.
    Muz B; de la Puente P; Azab F; Luderer MJ; King J; Vij R; Azab AK
    Br J Haematol; 2016 Apr; 173(1):70-81. PubMed ID: 26729247
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The role of circulating miRNAs in multiple myeloma.
    Zhang J; Xiao X; Liu J
    Sci China Life Sci; 2015 Dec; 58(12):1262-9. PubMed ID: 26607481
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Utility of hematology analyzer and flow cytometry in timely and correct detection of circulating plasma cells: Report of three cases.
    Gounari E; Tsavdaridou V; Koletsa T; Nikolaidou A; Kaiafa G; Papaioannou M; Kostopoulos I; Skoura L
    Cytometry B Clin Cytom; 2016 Nov; 90(6):531-537. PubMed ID: 26663635
    [TBL] [Abstract][Full Text] [Related]  

  • 67. High density of tryptase-positive mast cells in patients with multiple myeloma: correlation with parameters of disease activity.
    Devetzoglou M; Vyzoukaki R; Kokonozaki M; Xekalou A; Pappa CA; Papadopoulou A; Alegakis A; Androulakis N; Alexandrakis MG
    Tumour Biol; 2015 Nov; 36(11):8491-7. PubMed ID: 26026586
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Circulating plasma cells with Russell bodies in osteosclerotic myeloma.
    Chen M; Green R
    Blood; 2013 Jul; 122(2):160. PubMed ID: 24006527
    [No Abstract]   [Full Text] [Related]  

  • 69. Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents.
    Terpos E; Anargyrou K; Katodritou E; Kastritis E; Papatheodorou A; Christoulas D; Pouli A; Michalis E; Delimpasi S; Gkotzamanidou M; Nikitas N; Koumoustiotis V; Margaritis D; Tsionos K; Stefanoudaki E; Meletis J; Zervas K; Dimopoulos MA;
    Int J Cancer; 2012 Feb; 130(3):735-42. PubMed ID: 21484787
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma.
    Woitge HW; Pecherstorfer M; Horn E; Keck AV; Diel IJ; Bayer P; Ludwig H; Ziegler R; Seibel MJ
    Br J Cancer; 2001 Feb; 84(3):344-51. PubMed ID: 11161399
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    López-Pérez R; García-Sanz R; González D; Balanzategui A; Chillón MC; Alaejos I; Mateos MV; Caballero MD; Corral M; Orfão A; González M; San Miguel JF
    Bone Marrow Transplant; 2001 Oct; 28(7):665-72. PubMed ID: 11704789
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form.
    Rago A; Grammatico S; Za T; Levi A; Mecarocci S; Siniscalchi A; De Rosa L; Felici S; Bongarzoni V; Piccioni AL; La Verde G; Pisani F; Franceschini L; Paviglianiti AL; Caravita T; Petrucci MT; De Stefano V; Cimino G;
    Cancer; 2012 Nov; 118(22):5544-9. PubMed ID: 22786730
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Identification of malignant cells in multiple myeloma bone marrow with immunoglobulin VH gene probes by fluorescent in situ hybridization and flow cytometry.
    Cao J; Vescio RA; Hong CH; Kim A; Lichtenstein AK; Berenson JR
    J Clin Invest; 1995 Mar; 95(3):964-72. PubMed ID: 7883997
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Detection of myeloma cells in peripheral blood using multi-parameter flow cytometry: monitoring residual disease].
    Klabusay M; Doubek M; Adam Z; Hájek R; Krivanová A
    Cas Lek Cesk; 2000 Jul; 139(14):432-6. PubMed ID: 11048405
    [TBL] [Abstract][Full Text] [Related]  

  • 75. FLOCK cluster analysis of plasma cell flow cytometry data predicts bone marrow involvement by plasma cell neoplasia.
    Dorfman DM; LaPlante CD; Li B
    Leuk Res; 2016 Sep; 48():40-5. PubMed ID: 27479652
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Relationship of P-selectin glycoprotein ligand-1 to prognosis in patients with multiple myeloma.
    Atalay F; Ateşoğlu EB; Yıldız S; Firatlı-Tuglular T; Karakuş S; Bayık M
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):164-70. PubMed ID: 25445472
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clear cell myeloma artefactual or real.
    Pandey V; Khatib Y; Khade AL; Pandey R; Khare MS
    Indian J Pathol Microbiol; 2018; 61(1):159-161. PubMed ID: 29567916
    [No Abstract]   [Full Text] [Related]  

  • 78. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.
    Lakshman A; Rajkumar SV; Buadi FK; Binder M; Gertz MA; Lacy MQ; Dispenzieri A; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
    Blood Cancer J; 2018 Jun; 8(6):59. PubMed ID: 29895887
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Clinicopathologic characteristics of plasma cell myeloma with marrow fibrosis].
    Li HL; Ru K; Sun Q; Li ZQ; Zhang HJ; Ma Y; Xian M; Qiu LG; Liu EB
    Zhonghua Bing Li Xue Za Zhi; 2017 May; 46(5):327-331. PubMed ID: 28468039
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.